All In Biotech

Drug Trial Radar · NCT06953583

A Study to Learn More About the Effects and Long-Term Safety of Omaveloxolone (BIIB141) in Children and Teens With Friedreich's Ataxia

A Phase 3 Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Omaveloxolone (BIIB141) in Participants With Friedreich's Ataxia Aged 2 to < 16 Years

Last checked: Nov 19, 2026Latest source record: Oct 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 255 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

255

Planned (sponsor's estimate)

Start

Jun 9, 2025

Primary completion

Nov 16, 2027

Study completion Nov 22, 2029

Sponsor

Lead sponsor
BiogenBiogen (BIIB)
Sponsor type
Industry
First posted
May 1, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years, up to 15 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In this study, researchers will learn more about omaveloxolone, also known as BIIB141 or SKYCLARYS®. Omaveloxolone is already approved for people with Friedreich's Ataxia (FA) who are 16 years of age or older. However, it is not yet available for younger teens and children. The main goal of this study is to learn how omaveloxolone affects symptoms of FA and its safety in younger participants between the ages of 2 and 15 years old. The main questions researchers want to answer in this study are: * How does omaveloxolone affect the participants' FA symptoms? * How does the body process omaveloxolone? * How many participants have adverse events during the study? Adverse events are health problems that may or may not be caused by the study drug. * Are there any changes in the participants' overall health or heart health? Researchers will use the modified Friedreich's Ataxia Rating Scale (mFARS) to test nerve function. The mFARS tests movement ability, balance, coordination, speech, and arm and leg functions. More specifically, researchers will check participants' balance, coordination, movement, and ability to perform daily tasks using the Upright Stability Score (USS). The USS is part of the mFARS questionnaire. Researchers will also use other questionnaires to learn more about participants' symptoms, quality of life, ability to perform daily living activities, and how severe participants think their disease is. Researchers will also note any changes as participants go through puberty. Some participants may also be invited to take part in interviews about their experiences during the study or wear devices that measure movement and physical activity during daily life. This study will be done in 2 parts as follows: * Participants will be screened for up to 4 weeks to check if they can join the study. * In Part 1, participants will be randomly assigned to take either omaveloxolone or a placebo by mouth once a day for about 1 year. A placebo looks like the study drug but contains no real medicine. * Part 1 will be double blind. This means that the participants, study doctors, and study staff will not know if the participants are receiving omaveloxolone or a placebo. * Including screening, participants will have up to 9 clinic visits and 1 phone call during Part 1. If a participant does not join Part 2, they will have another safety follow-up phone call a month after their last dose of omaveloxolone. * Participants who finish Part 1 may move onto Part 2. During Part 2, participants who are at least 7 years old will be randomly assigned to receive either 150 mg or 250 mg of omaveloxolone once a day for about 104 weeks. Participants younger than 7 years old will receive 150 mg of omaveloxolone once a day for about 104 weeks. * During Part 2, participants will have up to 8 clinic visits and 1 phone call. Participants will also have a follow-up phone call about a month after they stop taking omaveloxolone. * In total, participants will have up to 17 clinic visits and 3 phone calls. Each participant will be in the study for up to 3 years.

Conditions

  • Friedreich Ataxia

Interventions

  • OmaveloxoloneDrug

    Administered as specified in the treatment arm.

  • PlaceboDrug

    Administered as specified in the treatment arm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Change From Baseline in Upright Stability Score (USS) Subscale E of Modified Friedreich's Ataxia Rating Scale (mFARS) at Week 52Time frame: Baseline, Week 52
  2. Part 2A: Change From Baseline in USS Subscale E of mFARS at Week 52Time frame: Baseline (Week 52 of Part 1), Week 52
  3. Part 2B: Number of Participants With Treatment-Emergent Adverse Event (TEAE) and Treatment-Emergent Serious Adverse Event (TESAE)Time frame: From the first dose of the study drug in Part 2B up to the end of follow-up period in Part 2B (up to Week 104)
  4. Part 2B: Number of Participants With Change From Baseline in Cardiac Function Assessed by Echocardiogram (ECHO) at Weeks 52 and Week 104Time frame: Baseline (Week 52 of Part 1), Weeks 52 and 104
  5. Part 2B: Change From Baseline in Height at Weeks 52 and Week 104Time frame: Baseline (Week 52 of Part 1), Weeks 52 and 104
  6. Part 2B: Change From Baseline in Weight at Weeks 52 and Week 104Time frame: Baseline (Week 52 of Part 1), Weeks 52 and 104
  7. Part 2B: Change From Baseline in Body Mass Index (BMI) at Weeks 52 and Week 104Time frame: Baseline (Week 52 of Part 1), Weeks 52 and 104
  8. Part 2B: Change From Baseline in Columbia Suicide Severity Rating Scale (C-SSRS) at Weeks 52 and Week 104Time frame: Baseline (Week 52 of Part 1), Weeks 52 and 104
  9. Part 2B: Percentage of Participants at Each Tanner Stage at Weeks 52 and Week 104Time frame: Baseline (Week 52 of Part 1), Weeks 52 and 104
  10. Part 2B: Number of Participants at Each Tanner Stage at Weeks 52 and Week 104Time frame: Baseline (Week 52 of Part 1), Weeks 52 and 104

Locations

34 sites in 16 countries. Site status is shown where the registry gives one.

  • UCLA Neurology Outpatient Clinic at Westwood

    Los Angeles, California

  • Norman Fixel Institute for Neurological Diseases UF Health

    Gainesville, Florida

  • USF Health Morsani College of Medicine Department of Neurology

    Tampa, Florida

  • Children's Hospital of Philadelphia - Buerger Center for Advanced Pediatric Care - PIN

    Philadelphia, Pennsylvania

  • St. Jude Children's Research Hospital - PIN

    Memphis, Tennessee

  • CHKD's Health Center - South Campus - PIN

    Norfolk, Virginia

  • Seattle Children's Hospital

    Seattle, Washington

  • Sydney Children's Hospital

    Randwick, New South Wales, Australia

  • Murdoch Childrens Research Institute (MCRI)

    Parkville, Victoria, Australia

  • Universitätsklinikum Innsbruck

    Innsbruck, Austria

  • L2 Ip - Instituto de Pesquisas Clinicas Ltda - ME

    Brasília, Federal District, Brazil

  • University of Campinas (UNICAMP) School of Medical Sciences

    Campinas, São Paulo, Brazil

  • PSEG Centro de Pesquisa Clinica

    São Paulo, São Paulo, Brazil

  • McGill University

    Montreal, Quebec, Canada

  • CHU de Quebec -Universite Laval

    Québec, Quebec, Canada

  • Rigshospitalet - Juliane Marie Centret (JMC) Copenhagen

    Copenhagen, Denmark

  • AP-HP - Hôpital Armand Trousseau

    Paris, France

  • CHU de Montpellier- Hôpital Gui De Chauliac

    Montpellier, Hérault, France

  • UKGM - Universitätsklinikum Giessen und Marburg GmbH - Standort Gießen

    Giessen, Germany

  • Universitätsklinikum Hamburg Eppendorf

    Hamburg, Germany

  • Universitätsklinikum Aachen

    Aachen, North Rhine-Westphalia, Germany

  • All India Institute of Medical Sciences (AIIMS) - New Delhi

    New Delhi, National Capital Territory of Delhi, India

  • CHI at Temple Street

    Dublin, Ireland

  • Fondazione IRCCS Istituto Neurologico Carlo Besta

    Milan, Italy

  • Ospedale Pediatrico Bambino Gesù IRCCS

    Rome, Lazio, Italy

  • IRCCS Eugenio Medea - Polo. Scientifico Veneto

    Conegliano, Veneto, Italy

  • Radboud Universitair Medisch Centrum

    Nijmegen, Netherlands

  • King Faisal Specialist Hospital & Research Centre

    Riyadh, Ar Riya, Saudi Arabia

  • Hospital Universitario La Paz - PPDS

    Madrid, Spain

  • Hospital Sant Joan de Deu - PIN

    Espluges de Llobregat, Barcelona, Spain

  • Istanbul Universitesi Istanbul Tip Fakultesi Hastanesi

    Istanbul, Turkey (Türkiye)

  • University College Hospital - PPDS

    London, Lincolnshire, United Kingdom

  • John Radcliffe Hospital

    Oxford, Oxfordshire, United Kingdom

  • Sheffield Children's Hospital - PPDS

    Sheffield, South Yorkshire, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.